URGN241220P10000
- 0.05
- 0.000.00%
UroGen Pharma Ltd Newsroom
UroGen Pharma Is Maintained at Buy by D. Boral Capital
UroGen Pharma Price Target Maintained With a $25.00/Share by D. Boral Capital
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Announces UGN-102 Long-Term Results In The Phase 3 ENVISION Trial, Potentially Paving The Way For First FDA-Approved Treatment For LG-IR-NMIBC; UGN-102 Demonstrated 82.3% Duration Of Response At 12 Months In Patients Who Achieved...
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
UroGen Pharma Presents New Data From A Long-Term Follow-Up Study Published In The Journal Of Urology Online To The OLYMPUS Trial Show Median Duration Of Response Of 4-Years In Patients Who Achieved A Complete Response With JELMYTO
New Data From a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response With JELMYTO
Further Weakness as UroGen Pharma (NASDAQ:URGN) Drops 13% This Week, Taking Five-year Losses to 64%
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript Summary
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $35
Express News | EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target
UroGen Pharma Ltd | 10-Q: Q3 2024 Earnings Report
UroGen Pharma Ltd | 8-K: UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
Express News | UroGen Pharma Expects Full-year 2024 JELMYTO Revenue To Be Below The Low End Of Previously Provided Guidance Range
UroGen Pharma Q3 2024 GAAP EPS $(0.55) Beats $(0.83) Estimate, Sales $25.20M Beat $24.20M Estimate
Press Release: UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
UroGen Pharma 3Q Loss $23.7M >URGN
UroGen Pharma 3Q Rev $25.2M >URGN